Your browser doesn't support javascript.
loading
IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors.
Beyranvand Nejad, Elham; Labrie, Camilla; van Elsas, Marit J; Kleinovink, Jan Willem; Mittrücker, Hans-Willi; Franken, Kees L M C; Heink, Sylvia; Korn, Thomas; Arens, Ramon; van Hall, Thorbald; van der Burg, Sjoerd H.
Affiliation
  • Beyranvand Nejad E; Medical Oncology, Oncode institute, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands.
  • Labrie C; Medical Oncology, Oncode institute, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands.
  • van Elsas MJ; Medical Oncology, Oncode institute, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands.
  • Kleinovink JW; Medical Oncology, Oncode institute, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands.
  • Mittrücker HW; Department of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Franken KLMC; Department of Immunology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands.
  • Heink S; Experimental Neuroimmunology, Technische Universität München, Munchen, Bayern, Germany.
  • Korn T; Experimental Neuroimmunology, Technische Universität München, Munchen, Bayern, Germany.
  • Arens R; Department of Immunology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands.
  • van Hall T; Medical Oncology, Oncode institute, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands.
  • van der Burg SH; Medical Oncology, Oncode institute, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands shvdburg@lumc.nl.
J Immunother Cancer ; 9(4)2021 04.
Article in En | MEDLINE | ID: mdl-33879600
BACKGROUND: High serum interleukin (IL-6) levels may cause resistance to immunotherapy by modulation of myeloid cells in the tumor microenvironment. IL-6 signaling blockade is tested in cancer, but as this inflammatory cytokine has pleiotropic effects, this treatment is not always effective. METHODS: IL-6 and IL-6R blockade was applied in an IL-6-mediated immunotherapy-resistant TC-1 tumor model (TC-1.IL-6) and immunotherapy-sensitive TC-1. CONTROL: Effects on therapeutic vaccination-induced tumor regression, recurrence and survival as well on T cells and myeloid cells in the tumor microenvironment were studied. The effects of IL-6 signaling in macrophages under therapy conditions were studied in Il6rafl/fl×LysMcre+ mice. RESULTS: Our therapeutic vaccination protocol elicits a strong tumor-specific CD8+ T-cell response, leading to enhanced intratumoral T-cell infiltration and recruitment of tumoricidal macrophages. Blockade of IL-6 signaling exacerbated tumor outgrowth, reflected by fewer complete regressions and more recurrences after therapeutic vaccination, especially in TC-1.IL-6 tumor-bearing mice. Early IL-6 signaling blockade partly inhibited the development of the vaccine-induced CD8+ T-cell response. However, the main mechanism was the malfunction of macrophages during therapy-induced tumor regression. Therapy efficacy was impaired in Il6rafl/fl×LysMcre+ but not cre-negative control mice, while no differences in the vaccine-induced CD8+ T-cell response were found between these mice. IL-6 signaling blockade resulted in decreased expression of suppressor of cytokine signaling 3, essential for effective M1-type function in macrophages, and increased expression of the phagocytic checkpoint molecule signal-regulatory protein alpha by macrophages. CONCLUSION: IL-6 signaling is critical for macrophage function under circumstances of immunotherapy-induced tumor tissue destruction, in line with the acute inflammatory functions of IL-6 signaling described in infections.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Oligodeoxyribonucleotides / Interleukin-6 / Cancer Vaccines / Papillomavirus E7 Proteins / Tumor-Associated Macrophages / Neoplasms Type of study: Guideline / Prognostic_studies Limits: Animals Language: En Year: 2021 Type: Article

Full text: 1 Database: MEDLINE Main subject: Oligodeoxyribonucleotides / Interleukin-6 / Cancer Vaccines / Papillomavirus E7 Proteins / Tumor-Associated Macrophages / Neoplasms Type of study: Guideline / Prognostic_studies Limits: Animals Language: En Year: 2021 Type: Article